The Peptide Revolution.

Peptides are short chains of amino acids — the same "building blocks" that make up all the proteins in the human body. Dr. Alex Tatem, a urologist and men's-health specialist interviewed on The Diary of a CEO, compares them to LEGO bricks: "My son can take the same set of LEGOs and build a rocket ship, a pirate ship, and a race car." The pieces are identical; the combination is everything.

The important thing about peptides is that they are highly targeted. Most traditional medicines (so-called "small molecules") work like a hammer — they can do many jobs, but they often cause side effects because they affect many parts of the body at once. A peptide is more like a specific key that fits one specific lock: a single receptor on a cell. This means peptides can produce powerful effects with, in theory, fewer unwanted consequences.

Peptides are not a new idea. The first peptide drug was insulin, isolated in 1921. Since then, scientists have developed peptides for fertility, cancer, weight loss, sleep, and skin repair — and the list keeps growing.

So why has the word "peptide" suddenly exploded across social media? Searches for the term have risen by about 400 percent recently. The answer lies partly in biology and partly in politics — a story of court rulings, FDA regulation, and billions of dollars in potential profits.

In 2013, the US Supreme Court made a landmark decision: a company called Myriad Genetics could not patent a naturally occurring human gene. The ruling was a victory for patients, but it had an unexpected side effect. Pharmaceutical companies suddenly had no financial incentive to develop natural compounds like peptides, because they could no longer own them. Drug development costs hundreds of millions of dollars, and no public company will invest that without a patent.

For several years, peptides continued to be produced by compounding pharmacies — small, specialised laboratories that prepare custom medications for individual patients. Doctors prescribed them, patients injected them, and few problems were reported.

Then, in 2023, the FDA abruptly moved 19 popular peptides to "Category 2" — effectively banning them from compounding. The official reason was "insufficient safety data", but many observers, including Dr. Tatem, suspect commercial pressure played a role. Big pharmaceutical companies cannot patent peptides that already exist in nature, but every dollar spent on a peptide is a dollar not spent on their products.

On 15 April 2025, the FDA announced it would reconsider seven of these peptides in July, potentially returning them to legal status. The names on the list — BPC-157, TB-500, KPV, MOTS-c, DSIP, Epithalon, and Semax — represent a significant shift in US policy toward natural compounds.